GO:0097327 response to antineoplastic agent: Cellular Stress Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097327 (response to antineoplastic agent) describes any cellular or organismal change triggered by a substance that inhibits or prevents neoplasm proliferation, as defined by QuickGO.
• The response encompasses diverse processes including DNA damage repair, apoptosis, cell cycle arrest, stress pathway activation, and altered drug metabolism [1,2].
• Key genes involved include TP53, CDKN1A, BAX, BCL2, MDM2, and ABC transporters, which mediate sensitivity or resistance to antineoplastic agents [1,2].
• Antineoplastic agents such as cisplatin, capecitabine, fludarabine, bendamustine, and thapsigargin induce distinct transcriptional and signaling responses that can be studied with CRISPR models [1,3,4,5,8].
• Understanding this response is critical for predicting drug efficacy, overcoming resistance, and identifying biomarkers for personalized cancer therapy [1,2].
• EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, and library screening services to dissect the genetic basis of response to antineoplastic agents.
Description
The Gene Ontology term GO:0097327, response to antineoplastic agent, defines the collection of cellular and organismal processes that occur when a cell or organism encounters a chemical substance capable of inhibiting or preventing the proliferation of neoplasms. This term is essential for annotating gene products that mediate drug sensitivity, resistance, and toxicity in cancer research. Antineoplastic agents include classical chemotherapeutics like cisplatin, antimetabolites like capecitabine, and natural product-derived compounds such as thapsigargin, each eliciting complex signaling and transcriptional changes [1,4,8]. The response involves activation of DNA damage checkpoints, stress-responsive pathways, and apoptotic machinery, as well as alterations in drug transport and metabolism [1,2]. Researchers studying this term aim to identify the molecular determinants of drug response, which can inform the development of more effective and less toxic cancer therapies. The systematic review by Crona et al. highlights the clinical importance of understanding cellular responses to cisplatin to prevent nephrotoxicity. Similarly, Okunaka et al. demonstrated that antineoplastic agent-induced diarrhea involves nuclear receptor and stress response pathways, underscoring the broad physiological impact of these agents. Thus, GO:0097327 serves as a unifying framework for investigating how cells react to anticancer drugs, with implications for drug discovery, resistance mechanisms, and personalized medicine.
response to antineoplastic agent At A Glance
| GO ID | GO:0097327 |
|---|---|
| GO term | response to antineoplastic agent |
| Ontology | biological_process |
| Synonym | none |
| Major function | Mediates cellular and organismal changes triggered by anticancer drugs, including stress responses, apoptosis, and drug metabolism. |
| Definition source | QuickGO |
| Related processes | DNA damage response, apoptosis, cell cycle arrest, stress signaling, drug transport |
| Key regulators | TP53, CDKN1A, BAX, BCL2, MDM2, ABCB1, ABCC1, CYP enzymes |
| Disease relevance | Cancer chemoresistance, drug toxicity, personalized therapy |
What Is GO:0097327?
GO:0097327, response to antineoplastic agent, is a biological process defined by QuickGO as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an antineoplastic agent stimulus. An antineoplastic agent is a substance that inhibits or prevents the proliferation of neoplasms. In other words, it captures all molecular and cellular events triggered when a cell encounters a chemotherapy drug or any compound with anticancer activity, including changes in gene expression, signaling, metabolism, and survival.
Why Is response to antineoplastic agent Important in Cell Biology?
Understanding GO:0097327 is crucial because the cellular response to antineoplastic agents determines therapeutic success or failure. It influences drug sensitivity, resistance, and adverse effects, and is central to developing biomarkers and targeted strategies to improve cancer treatment [1,2].
• Predicts patient response to chemotherapy and guides treatment selection.
• Reveals mechanisms of chemoresistance, enabling strategies to overcome it.
• Helps identify biomarkers for drug toxicity, such as cisplatin-induced nephrotoxicity.
• Provides insight into adverse effects like diarrhea caused by antineoplastic agents.
• Facilitates drug discovery by elucidating pathways targeted by new agents.
• Supports personalized medicine through genetic profiling of response pathways [1,2].
• Enables functional genomics studies using CRISPR screens to identify modifiers of drug response.
• Links basic cancer biology to clinical outcomes, bridging bench and bedside [1,2].
What Happens During response to antineoplastic agent?
Drug Uptake and Initial Sensing
In simple terms: The cell first takes in the drug and recognizes it as a threat.
Antineoplastic agents enter cells through passive diffusion or active transport. Once inside, they interact with cellular targets such as DNA, microtubules, or metabolic enzymes. This initial sensing triggers early signaling events, including activation of stress kinases and transcription factors. For example, cisplatin forms DNA adducts that are recognized by DNA damage sensors, leading to activation of the DNA damage response. Capecitabine, a prodrug of 5-fluorouracil, is metabolized intracellularly to inhibit thymidylate synthase and incorporate into RNA and DNA, causing metabolic stress. The initial sensing phase is critical for determining the subsequent cellular fate.
Activation of Stress and Survival Pathways
In simple terms: The cell turns on emergency signals that decide whether to repair damage or self-destruct.
Following drug exposure, cells activate a network of stress-responsive pathways. The nuclear factor erythroid 2-related factor 2 (NRF2) pathway, antioxidant response, and unfolded protein response are commonly engaged. Okunaka et al. showed that antineoplastic agent-induced diarrhea involves nuclear receptor and stress response pathways, highlighting the systemic impact of these agents. The p53 tumor suppressor is a central mediator that coordinates cell cycle arrest, DNA repair, and apoptosis in response to many antineoplastic agents. Additionally, the PI3K/AKT/mTOR pathway often promotes survival and can contribute to drug resistance. The balance between pro-survival and pro-death signals determines the cellular outcome.
DNA Damage Response and Cell Cycle Checkpoints
In simple terms: If the drug damages DNA, the cell pauses division to fix it or triggers self-destruction.
Many antineoplastic agents, such as cisplatin and bendamustine, cause DNA damage. This activates the DNA damage response (DDR), including ATM/ATR kinases, CHK1/CHK2, and p53. p53 induces CDKN1A (p21), causing cell cycle arrest at G1/S or G2/M checkpoints. If damage is severe, p53 promotes apoptosis via BAX and PUMA. Bendamustine, a bifunctional alkylating agent, induces DNA crosslinks and triggers p53-dependent apoptosis. Fludarabine, a purine analog, inhibits DNA synthesis and induces apoptosis in chronic lymphocytic leukemia cells. The DDR is a critical determinant of drug sensitivity.
Apoptosis and Cell Death Execution
In simple terms: When damage is too severe, the cell activates a self-destruct program.
Apoptosis is a major mode of cell death induced by antineoplastic agents. It involves mitochondrial outer membrane permeabilization, release of cytochrome c, activation of caspases, and DNA fragmentation. BAX and BAK are pro-apoptotic effectors, while BCL-2 and BCL-XL are anti-apoptotic. Thapsigargin, a sesquiterpene lactone, induces apoptosis by disrupting calcium homeostasis in the endoplasmic reticulum. Nanoliposomal ceramide triggers apoptosis in hepatocellular carcinoma cells. Evodiamine-based nitroreductase responsive agents induce apoptosis in colon cancer cells. The intrinsic and extrinsic apoptotic pathways are often co-opted by antineoplastic agents.
Drug Efflux and Metabolic Inactivation
In simple terms: The cell tries to pump the drug out or break it down to survive.
Cells can reduce drug efficacy by increasing efflux via ATP-binding cassette (ABC) transporters such as ABCB1 (P-glycoprotein) and ABCC1, or by metabolizing the drug through phase I and II enzymes. This contributes to chemoresistance. For example, overexpression of ABCB1 reduces intracellular accumulation of taxanes and anthracyclines. Additionally, glutathione conjugation and UDP-glucuronosyltransferases can inactivate drugs. The response to antineoplastic agents thus includes adaptive mechanisms that limit drug action, which are important targets for overcoming resistance [1,2].
Key Genes Involved in GO:0097327 response to antineoplastic agent
The following genes are central to the cellular response to antineoplastic agents, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Master transcription factor inducing cell cycle arrest, apoptosis, and DNA repair | Mutations in TP53 alter drug sensitivity and are common in cancers |
| CDKN1A | p21, mediates p53-dependent cell cycle arrest | Biomarker of drug-induced senescence and response |
| BAX | Pro-apoptotic BCL-2 family member | Effector of mitochondrial apoptosis; predicts drug response |
| BCL2 | Anti-apoptotic protein | Overexpression confers chemoresistance; target for inhibitors |
| MDM2 | Negative regulator of p53 | Amplification inactivates p53, reducing drug sensitivity |
| ABCB1 | Drug efflux pump (P-glycoprotein) | Mediates multidrug resistance |
| ABCC1 | Multidrug resistance-associated protein 1 | Exports glutathione-conjugated drugs |
| CYP3A4 | Cytochrome P450 enzyme metabolizing many drugs | Influences drug clearance and efficacy |
| NR1I2 | Pregnane X receptor, regulates drug-metabolizing enzymes | Nuclear receptor pathway in antineoplastic-induced diarrhea |
| NFE2L2 | NRF2, antioxidant response transcription factor | Protects against drug-induced oxidative stress |
| ATF4 | Integrated stress response transcription factor | Mediates adaptation to drug-induced stress |
| CASP3 | Executioner caspase in apoptosis | Marker of drug-induced apoptosis |
| CASP9 | Initiator caspase in intrinsic apoptosis | Activated by cytochrome c release |
| BID | BH3-only protein linking extrinsic and intrinsic apoptosis | Amplifies death receptor signaling |
| XBP1 | Unfolded protein response transcription factor | Regulates ER stress response to drugs |
| HSPA5 | BiP, ER chaperone | Sensor of ER stress induced by thapsigargin |
| TOP1 | Topoisomerase I, target of irinotecan | Inhibition leads to DNA damage |
How Is response to antineoplastic agent Regulated?
The response to antineoplastic agents is tightly regulated at multiple levels. Transcriptional regulation involves p53, NRF2, HIF1A, and nuclear receptors such as NR1I2, which control genes involved in DNA repair, antioxidant defense, and drug metabolism [1,2]. Post-translational modifications, including phosphorylation by ATM/ATR and ubiquitination by MDM2, modulate protein stability and activity. Non-coding RNAs, such as microRNAs, can fine-tune the expression of drug response genes. Additionally, epigenetic mechanisms like DNA methylation and histone acetylation influence drug sensitivity. The integrated stress response (ISR) and mTOR signaling are key nodes that integrate nutrient and stress signals to determine cell fate. Understanding these regulatory layers is essential for predicting drug response and designing combination therapies.
response to antineoplastic agent and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Li-Fraumeni syndrome, chemoresistance | TP53 knockout and point-mutant knock-in cell lines |
| BCL2 | Follicular lymphoma, chemoresistance | BCL2 overexpression and knockout models |
| ABCB1 | Multidrug resistance in leukemia and solid tumors | ABCB1 knockout and overexpression in cancer cell lines |
| NR1I2 | Antineoplastic-induced diarrhea | NR1I2 knockout mouse models and intestinal organoids |
| XBP1 | ER stress response in cancer | XBP1 knockout and overexpression in cancer cells |
Cancer Chemoresistance
Alterations in genes mediating the response to antineoplastic agents, such as TP53 mutations, BCL2 overexpression, or ABCB1 upregulation, lead to chemoresistance and treatment failure in many cancers. Understanding these mechanisms can guide the development of targeted therapies to overcome resistance.
Drug-Induced Toxicity
The same pathways that mediate tumor cell killing can cause toxicity in normal tissues. For example, cisplatin-induced nephrotoxicity involves DNA damage and oxidative stress in renal tubular cells. Antineoplastic agent-induced diarrhea is associated with nuclear receptor and stress response pathways in the gut. Identifying genetic variants that predispose to toxicity can improve patient safety.
Hepatocellular Carcinoma
Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma by inducing apoptosis and modulating the response to antineoplastic agents. This highlights the potential of targeting sphingolipid metabolism in liver cancer.
Colon Cancer
Evodiamine-based nitroreductase responsive theranostic agents are designed to treat colon cancer by exploiting tumor-specific nitroreductase activity to release cytotoxic agents, thereby inducing DNA damage and apoptosis. This exemplifies how understanding drug response mechanisms can lead to innovative therapeutics.
From response to antineoplastic agent-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TP53 alter sensitivity to cisplatin? | TP53 knockout cancer cell lines (e.g., HCT116, A549) |
| Does a specific point mutation in BCL2 confer resistance to apoptosis? | BCL2 point-mutant knock-in cell lines |
| Can overexpression of ABCB1 induce multidrug resistance? | ABCB1 overexpression in drug-sensitive cell lines |
| What is the role of NR1I2 in antineoplastic-induced diarrhea? | NR1I2 knockout mouse model and intestinal organoids |
| Does tagging of MDM2 with a fluorescent protein affect its localization after drug treatment? | MDM2 tagged knock-in cell lines |
| Which genes modulate response to capecitabine? | Genome-wide CRISPR knockout library screening in colorectal cancer cells |
How to Study the response to antineoplastic agent Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify pathways activated by antineoplastic agents |
| Phosphoproteomics | Protein phosphorylation dynamics | Map DNA damage signaling after cisplatin |
| CRISPR knockout screen | Genes required for drug sensitivity/resistance | Discover modifiers of capecitabine response |
| CRISPR activation screen | Genes whose overexpression confers resistance | Identify drug resistance drivers |
| High-content imaging | Cell morphology, apoptosis, cell cycle | Quantify drug-induced phenotypic changes |
| Flow cytometry | Apoptosis, cell cycle, surface markers | Measure drug-induced cell death |
| Western blot | Protein expression and cleavage | Detect caspase activation and BCL2 family proteins |
| qRT-PCR | mRNA levels of specific genes | Validate RNA-seq findings for drug response genes |
Transcriptomic Profiling
RNA sequencing (RNA-seq) is widely used to measure global changes in gene expression following treatment with antineoplastic agents. This can reveal activation of stress pathways, apoptosis, and drug metabolism. For example, Okunaka et al. used transcriptomic analysis to identify nuclear receptor and stress response pathways associated with antineoplastic agent-induced diarrhea. RNA-seq can be combined with CRISPR screens to identify transcriptional regulators of drug response.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based proteomics can quantify changes in protein abundance and post-translational modifications after drug exposure. This is particularly useful for studying DNA damage response signaling, where phosphorylation events are critical. For instance, cisplatin-induced DNA damage leads to phosphorylation of ATM, ATR, and p53, which can be monitored by phosphoproteomics. Proteomics can also identify novel drug targets and resistance mechanisms.
Functional Genomics with CRISPR Screens
CRISPR knockout and activation screens enable unbiased identification of genes that modulate sensitivity to antineoplastic agents. Libraries targeting all human genes can be introduced into cancer cell lines, followed by drug treatment and sequencing to identify enriched or depleted sgRNAs. This approach has been used to discover genes involved in cisplatin and capecitabine response [1,4]. CRISPR screens are powerful for uncovering novel therapeutic targets and biomarkers.
Imaging and Cell-Based Assays
High-content imaging and flow cytometry can assess drug-induced apoptosis, cell cycle arrest, and DNA damage at the single-cell level. For example, immunofluorescence for γH2AX detects DNA double-strand breaks after cisplatin treatment. Live-cell imaging of fluorescently tagged proteins (e.g., BAX, cytochrome c) can reveal mitochondrial dynamics during apoptosis. These methods complement genomic and proteomic approaches.
How CRISPR Can Be Used to Study GO:0097327 response to antineoplastic agent
Knockout
CRISPR knockout is used to delete genes hypothesized to mediate response to antineoplastic agents. For example, knocking out TP53 in cancer cell lines can test its requirement for cisplatin-induced apoptosis. Knockout of ABCB1 can reverse multidrug resistance. Genome-wide knockout screens are powerful for identifying novel genes that modulate drug sensitivity.
Point Mutation
Point mutations can be introduced to model clinically relevant variants. For instance, knock-in of the TP53 R175H mutation can assess its dominant-negative effect on drug response. Point mutations in BCL2 that alter its anti-apoptotic activity can be studied to understand resistance mechanisms. CRISPR prime editing and homology-directed repair enable precise point mutation introduction.
Knock-in
Knock-in of reporter genes or tags allows visualization and tracking of proteins involved in drug response. For example, knocking in a fluorescent tag at the endogenous MDM2 locus enables live-cell imaging of MDM2 dynamics after drug treatment. Knock-in of drug-responsive promoters driving luciferase can create biosensors for high-throughput screening.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can be used to study gain-of-function effects. Overexpressing BCL2 or ABCB1 can confer resistance to apoptosis or drug efflux, respectively. Overexpression of NRF2 can protect against oxidative stress induced by antineoplastic agents. These models help validate candidate resistance genes.
How EDITGENE Supports response to antineoplastic agent Research
Researchers studying response to antineoplastic agent-related genes often need to determine whether a candidate gene is causally involved in drug sensitivity, resistance, or toxicity. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models, enabling functional validation of genes identified from screens or clinical data.
Contact EDITGENE today to design your custom CRISPR model for response to antineoplastic agent research.
Frequently Asked Questions About response to antineoplastic agent
What is GO:0097327 response to antineoplastic agent?
GO:0097327 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism as a result of an antineoplastic agent stimulus, where an antineoplastic agent inhibits or prevents neoplasm proliferation [1,2].
What genes are involved in response to antineoplastic agent?
Key genes include TP53, CDKN1A, BAX, BCL2, MDM2, ABCB1, ABCC1, CYP3A4, NR1I2, NFE2L2, ATF4, CASP3, CASP9, BID, XBP1, HSPA5, and TOP1, as supported by studies on cisplatin, capecitabine, and other agents [1,2,4,6,7,8].
How do antineoplastic agents trigger apoptosis?
Antineoplastic agents such as cisplatin, thapsigargin, and nanoliposomal ceramide induce apoptosis through DNA damage, ER stress, and mitochondrial outer membrane permeabilization, leading to caspase activation [1,6,8].
What is the role of p53 in response to antineoplastic agents?
p53 is a master transcription factor that induces cell cycle arrest, DNA repair, and apoptosis in response to drug-induced DNA damage, thereby determining sensitivity or resistance.
How is response to antineoplastic agent studied?
It is studied using RNA-seq, proteomics, CRISPR screens, imaging, and cell-based assays to measure gene expression, protein modifications, and phenotypic changes after drug treatment [1,2,4].
What causes chemoresistance to antineoplastic agents?
Chemoresistance can arise from mutations in TP53, overexpression of BCL2 or ABCB1, enhanced drug metabolism, and activation of survival pathways, as reviewed in the context of cisplatin and other agents [1,2].
Can CRISPR be used to study response to antineoplastic agents?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional validation of genes involved in drug response, and genome-wide screens can identify novel modifiers [1,4].
What is antineoplastic agent-induced diarrhea?
It is a common adverse effect of chemotherapy, associated with nuclear receptor and stress response pathways in the intestine, as shown by transcriptomic studies.
Which antineoplastic agents are used in research?
Common agents include cisplatin, capecitabine, fludarabine, bendamustine, thapsigargin, nanoliposomal ceramide, and evodiamine-based compounds [1,3,4,5,6,7,8].
How does EDITGENE support research on response to antineoplastic agents?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to generate and analyze cell models for studying drug response genes.
Conclusion
GO:0097327 response to antineoplastic agent encompasses the complex cellular and organismal changes triggered by anticancer drugs. Understanding these processes is essential for improving cancer therapy, overcoming resistance, and minimizing toxicity. The integration of CRISPR-based models with multi-omics approaches will continue to unravel the genetic and molecular determinants of drug response, paving the way for personalized medicine.
References
- 1. Crona DJ et al.. 2017. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.. Oncologist 22(5):609-619 PMID: 28438887
- 2. Okunaka M et al.. 2022. Nuclear Receptor and Stress Response Pathways Associated with Antineoplastic Agent-Induced Diarrhea.. Int J Mol Sci 23(20) PMID: 36293277
- 3. Balfour JA et al.. 2001. Bendamustine.. Drugs 61(5):631-8; discussion 639-40 PMID: 11368287
- 4. Budman DR. 2000. Capecitabine.. Invest New Drugs 18(4):355-63 PMID: 11081571
- 5. Plosker GL et al.. 2003. Oral fludarabine.. Drugs 63(21):2317-23 PMID: 14524733
- 6. Tagaram HR et al.. 2011. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma.. Gut 60(5):695-701 PMID: 21193455
- 7. Li K et al.. 2025. Evodiamine-Based Nitroreductase Responsive Theranostic Agents for Treatment of Colon Cancer.. J Med Chem 68(12):12402-12413 PMID: 40172237
- 8. Jaskulska A et al.. 2020. Thapsigargin-From Traditional Medicine to Anticancer Drug.. Int J Mol Sci 22(1) PMID: 33374919
